Europe seeks mRNA leadership amid US funding cuts

Shifts in United States vaccine policy and significant budget cuts are creating opportunities for Europe to lead in messenger RNA (mRNA) research. Following a federal disengagement under the administration of President Donald Trump, the US canceled approximately $500 million in grants and contracts dedicated to mRNA research and development. US Health Secretary Robert F. Kennedy Jr. announced that the Biomedical Advanced Research and Development Authority ended 22 investments in mRNA vaccine development, citing data that he claims showed vaccines did not effectively protect against upper respiratory infections like Covid-19 and influenza.

In response, global developers are increasingly turning to the European Medicines Agency (EMA) for regulatory guidance. EMA Executive Director Emer Cooke stated that the agency can provide neutral, fact-based information to establish the continent as a reliable hub for innovative science. However, industry leaders have raised concerns regarding manufacturing capacity. Moderna CEO Stéphane Bancel warned that Europe could make a strategic error if it loses its mRNA production capabilities. He noted that with BioNTech closing three production sites in Germany due to a lack of interested investors, the continent faces risks regarding preparedness for future pandemics.